AK
Akero
AKRO·NASDAQS San Francisco CAFounded 2017120 employees
Mid CapbiotechPublicMetabolicHepatology
Platform: Efruxifermin
Market Cap
$2.5B
All Drugs
3
Clinical Trials
6
Failed / Terminated
2
FDA Approved
2
Stock Price & Catalysts (AKRO)
Loading AKRO stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| AKR-4818 | AKR-4818 | Approved | 3 | CD20 | Urothelial CaHeart Failure | ||
| Terazumab | AKR-9024 | NDA/BLA | 2 | CD47 | CholangiocarcinomaHS | ||
| Zoriosocimab | AKR-1543 | Approved | 1 | C5 | MCCNB |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (5)